#STRATA ONCOLOGY SERIES#

By characterizing patients' tumors and then monitoring for MRD via a highly sensitive and specific liquid biopsy test, we can help their doctors make informed decisions as soon as possible about whether to put them on therapy, and whether a biomarker-matched targeted therapy, immunotherapy or antibody-drug conjugate may be optimal.' 'The hope for early-stage cancer patients is that their disease will be cured with their initial treatment, but we know many will have a recurrence.

'We see an incredible opportunity to bring the precision oncology advances we've seen in late-stage cancer to patients with early-stage disease,' said Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology. This brings Strata's total funding to $128M to date.Study will evaluate performance of tumor-informed ctDNA-based minimal residual disease (MRD) testing and clinical benefit of therapy in ctDNA-positive patientsĪNN ARBOR, Mich., Ma/PRNewswire/ - Strata Oncology, Inc., a precision oncology company advancing new molecular indications for cancer therapies, today announced enrollment of the first patient in the Strata Sentinel™ trial, a prospective, observational study that will evaluate the ability of the investigational StrataMRD ™ test to detect cancer recurrence in advance of standard of care techniques across solid tumors, as well as the clinical benefit of treatment in early-stage patients who are or become ctDNA-positive after surgery or other therapy with curative intent.

#STRATA ONCOLOGY SERIES#

The company raised $90M in Series C round on Jul 28, 2021. Strata is backed by Wellington Management, Pfizer Ventures, Cormorant Asset Management, Merck Global Health Innovation Fund, Monashee Investment Management, Deerfield Management, and others. It also offers Strata Precision Oncology Network, a collaborative network of cancer centers with a shared goal of accelerating precision medicine for cancer patients. Strata Partnered Trials, a portfolio of pharma-sponsored therapeutic protocols aligned to distinct biomarkers. Strata's products and services include The Strata Trial, a genomic testing protocol to implement systematic, enterprise-wide precision oncology StrataNGS, a targeted assay that sequences DNA and RNA in archival or fresh biopsy tissue StrataPOINT, that integrates EMR-based clinical histories with molecular profiling data to ensure that all eligible advanced cancer patients are tested. Their approach empowers health systems and catalyzes pharma trials so that more patients benefit and new medicines are available sooner. Strata Oncology is delivering a new way forward for precision oncology that is highly-scaled, systematic and data-driven. Strata Oncology was founded in 2016 by Dan Rhodes and Scott Tomlins. The company is based in Ann Arbor, Michigan. Strata empowers health systems to deliver a cost-effective, system-wide, precision oncology program, one that integrates cutting-edge molecular profiling and precision therapy trials with routine care, so that all advanced cancer patients have the opportunity to benefit.

Strata Oncology is a precision medicine company dedicated to transforming cancer care by systematizing precision oncology across a network of health systems and pharma companies.

Strata oncology